Slide 1: 9M 2020 Results
9M 2020 RESULTS November 11, 2020
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Financial Highlights
Financial Highlights Change Change Data in €/mln Q3’20 9M’20 @ current @ CER @ current @ CER Revenues 227.9 +30.3% +34.3% 610.1 +16.2% +17.2% CLIA ex Vitamin D +1.3% +4.8% +5.4% +6.7% Vitamin D -16.4% -13.3% -29.3% -28.6% ELISA tests -32.6% -30.1% -29.1% -28.4% Molecular tests +403.7% +415.1% +243.1
Slide 4: 9M 2020 key facts
9M 2020 key facts Immunodiagnostic Installed Base Product Development Immunodiagnostics: @ September 30, 2020 • LIAISON SARS-CoV-2 S1/S2 IgG: to identify IgG antibodies against S1 and S2 proteins of SARS-CoV-2 in human serum or plasma samples New placements of Liaison XL +416 • LIAISON SARS-CoV-2 Ig
Slide 5: Managerial outlook on Q3 & 9M 2020 revenues
Managerial outlook on Q3 & 9M 2020 revenues Total Group revenues Data in €/mln @ CER +17.2% 615.6 525.1 +34.3% 234.8 174.8 Q3 2019 Q3 2020 9M 2019 9M 2020 Key Q3 factors 9 months business affected differently in each quarter • MOLECULAR TESTS • Q1’20: positive results, despite negative impact from C
Slide 6: Focus: impact of COVID-19 pandemic at top line level
Focus: impact of COVID-19 pandemic at top line level +17.2% 615.6 525.1 +34.3% 234.8 (75,3) +165.8 -14.3% 174.8 (12.5) +72.5 -7.2% Q3 2019 Q3 2020 9M 2019 9M 2020 Change in business ex-COVID COVID-19 tests contribution Data in €/mln @ CER Managerial outlook on reported data; Change QoQ and 9M on 9M
Slide 7: Q3 & 9M 2020 revenue growth by technology
Q3 & 9M 2020 revenue growth by technology Total Group revenues Key impacting factors Q3'20 vs. Q3'19 9M'20 vs. 9M'19 • Ex-COVID testing volume decrease more than offset by COVID-19 tests‘ growth reported +1.3% +5.4% CLIA ex Vitamin D tests @ CER +4.8% +6.7% • Q3 ex-COVID volumes improving compared t
Slide 8: Q3 & 9M 2020 revenue trend by geography
Q3 & 9M 2020 revenue trend by geography Deep dive on COVID-19 impact on geographies Q3’20 vs. Q3’19 9M’20 vs. 9M’19 EUROPE & AFRICA • All countries recording positive top line trend in Q3, mainly thanks to the contribution +23.9% +13.8% of COVID-19 testing • Ex-COVID testing volume improved in Q3 US
Slide 9: 9M 2020 revenues breakdown @ current exchange rate
9M 2020 revenues breakdown @ current exchange rate BY GEOGRAPHY BY TECHNOLOGY Instruments & other revenues 9M’19 10.0% 9M'19 USA & Canada Molecular diagnostic tests 29.4% 8.8% Europe & Africa CLIA tests 46.2% ELISA tests 67.4% COVID molecular 13.8% COVID sales drive sales drive the Asia Pacific the
Slide 10: Q3'20 & 9M'20 profitability profile
Q3’20 & 9M’20 profitability profile DATA IN €/MLN Q3'19 Q3'20 Change % 9M'19 9M'20 Change % GROSS PROFIT 119.8 155.7 +29.9% 363.1 419.7 +15.6% EBITDA 69.7 104.1 +49.4% 208.9 257.7 +23.4% @ CER +54.2% +24.8% EBITDA MARGIN 39.9% 45.7% +583 bps 39.8% 42.2% +245 bps @CER 45.8% +590 bps 42.3% +255 bps EB
Slide 11: Company Guidance
Company Guidance Despite the uncertainty caused by new lockdown measures applied in most of the countries where the Group operates, DiaSorin expects the following for FY 2020: • REVENUES: growth ~25% @2019 CER vs. FY’19 • EBITDA Margin: ~43% @2019 CER vs. FY’19 11
Slide 12: Financial schemes
Financial schemes 12
Slide 13: Income Statement
Income Statement Q3 Change 9M Change (Amounts in million of euros) 2019 2020 amount % 2019 2020 amount % Net Revenues 174.8 227.9 +53.0 +30.3% 525.1 610.1 +85.0 +16.2% Cost of sales (55.0) (72.2) -17.2 +31.2% (162.0) (190.4) -28.4 +17.5% Gross profit 119.8 155.7 +35.8 +29.9% 363.1 419.7 +56.6 +15.6%
Slide 14: Balance Sheet
Balance Sheet (Amounts in million of euros) 12/31/2019 09/30/2020 Change Goodwill and intangibles assets 370.3 361.0 -9.2 Property, plant and equipment 128.4 129.6 +1.2 Net working capital 211.0 218.3 +7.3 Other non-current assets / (liabilities) (33.9) (59.3) -25.4 Net Invested Capital 675.7 649.6
Slide 15: Cash flow statement
Cash flow statement Q3 9M (Amounts in million of euros) 2019 2020 2019 2020 Cash and cash equivalents at the beginning of the period 90.1 138.7 73.1 157.6 Cash provided by operating activities 81.8 93.9 171.1 199.3 Cash used in investing activities (10.2) (15.7) (34.6) (47.1) Cash provided/(used) in
Slide 16: DiaSorin
DiaSorin